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After several years of latency, feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) cause
fatal disease in the cat. The aim of this study was to determine laboratory parameters characteristic of disease
progression which would allow a better description of the asymptomatic phase and a better understanding of
the pathogenesis of the two infections. Therefore, experimentally infected cats (FIV and/or FeLV positive) and
control animals were observed over a period of 6.5 years under identical conditions. Blood samples were
analyzed for the following: complete hematology, clinical chemistry, serum protein electrophoresis, and de-
termination of CD41 and CD81 lymphocyte subsets. The following hematological and clinical chemistry
parameters were markedly changed in the FIV-infected animals from month 9 onwards: glucose, serum protein,
gamma globulins, sodium, urea, phosphorus, lipase, cholesterol, and triglyceride. In FeLV infection, the
markedly changed parameters were mean corpuscular volume, mean corpuscular hemoglobin, aspartate
aminotransferase, and urea. In contrast to reports of field studies, neither FIV-positive nor FeLV-positive
animals developed persistent leukopenia, lymphopenia, or neutropenia. A significant decrease was found in the
CD41/CD81 ratio in FIV-positive and FIV-FeLV-positive animals mainly due to loss of CD41 lymphocytes. In
FeLV-positive cats, both CD41 and, to a lesser degree, CD81 lymphocytes were decreased in long-term
infection. The changes in FIV infection may reflect subclinical kidney dysfunction, changes in energy and lipid
metabolism, and transient activation of the humoral immune response as described for human immunodefi-
ciency virus (HIV) infections. The changes in FeLV infection may also reflect subclinical kidney dysfunction
and, in addition, changes in erythrocyte and immune function of the animals. No severe clinical signs were
observed in the FIV-positive cats, while FeLV had a severe influence on the life expectancy of persistently
positive cats. In conclusion, several parameters of clinical chemistry and hematology were changed in FIV and
FeLV infection. Monitoring of these parameters may prove useful for the evaluation of candidate FIV vaccines
and antiretroviral drugs in cats. The many parallels between laboratory parameters in FIV and HIV infection
further support the importance of FIV as a model for HIV.
Feline immunodeficiency virus (FIV) and feline leukemia
virus (FeLV) are retroviruses of cats which are found world-
wide under natural conditions (23, 32, 34, 48, 69). FIV infec-
tion leads to an immune suppression and to an AIDS-like
syndrome (20, 48). FeLV infection induces anemia, an AIDS-
like syndrome, and, less frequently, lymphomyeloproliferative
or neurologic disorders (14). Although the fatal outcome of
these two retrovirus infections is well known and feared, much
less is known about the preceding asymptomatic phase which
usually lasts several years. Parameters of clinical chemistry and
hematology have been studied in naturally infected cats (19,
57–59, 62, 68). However, the changes documented under field
conditions may not necessarily be attributed to the underlying
retrovirus infections. A broad variety of factors such as age and
living conditions of the animal or other infections may contrib-
ute to the observed changes, and the duration of the infection
usually is unknown. No information on the course of these
parameters in long-term experimental FeLV and FIV infec-
tions is available. Therefore, it was the goal of the present
study to monitor the course of as many parameters as possible
that can easily be determined in a diagnostic laboratory routine
to define those that are associated with FIV and/or FeLV
infection. We hoped to determine parameters characteristic of
disease progression which would allow a better description of
the asymptomatic phase and a better understanding of the
pathogenesis of the two infections. In addition, knowledge of
parameters of disease progression may be important for eval-
uation of antiretroviral drugs or vaccines. While efficacious
FeLV vaccines are readily available (28, 39), no FIV vaccines
have been introduced to the field. Today it appears likely that
FIV vaccines that protect against the development of disease
but not against infection can be designed (18, 35). Especially in
this latter context, monitoring parameters of disease progres-
sion will be important.
MATERIALS AND METHODS
Study design and cats. Specific-pathogen-free cats were experimentally in-
fected, observed, and sampled over several years: 15 cats were experimentally
infected with FIV strain Zurich 2 (46) at the age of 17 weeks (month 0) by
intraperitoneal application of 1 ml of cell culture supernatant containing FIV
Zurich 2, and 15 cats served as age-matched FIV-negative controls. In each
group, nine cats were vaccinated against FeLV infection with a recombinant
FeLV vaccine (28); all cats were subsequently challenged with FeLV by intra-
peritoneal application of 5 ml of cell culture supernatant containing 106 focus-
forming units of FeLV subtype A at month 10 (28). FIV was monitored by
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detection of antibodies (by enzyme-linked immunosorbent assay [ELISA] and
Western blot [immunoblot]) and by virus isolation from blood lymphocytes (33).
FeLV infection was monitored by detection of antibodies by the use of recom-
binant FeLV surface protein in an ELISA as described previously (28), by
detection of antigen p27 by a sandwich ELISA (37), and by virus isolation from
blood in a modified clone 81 assay (39). Latent FeLV infection was determined
by cultivation of bone marrow samples collected 24 weeks after FeLV infection
by procedures described previously (38). For the present study, the cats were
subsequently rearranged into four groups by their FeLV and FIV status: group
1, 10 FIV- and FeLV-negative controls; group 2, 10 FIV-positive cats; group 3,
5 persistently FeLV-positive cats; group 4, 5 FIV-positive and persistently FeLV-
positive animals. These animals were housed in a special facility of the Depart-
ment of Internal Veterinary Medicine, University of Zurich. They were fed
canned and dry cat food (Whiskas and Brekkies; Effems AG, Zug, Switzerland).
All cats were clinically examined weekly, and blood samples were collected
regularly. From a total of 74 blood collections over a period of 80 months, the
values of nine samplings in which all parameters were measured were statistically
evaluated. All time points are given with respect to the start of the experiment,
when FIV infection took place. Cats that had to be euthanized for humane
reasons underwent detailed necropsy and histopathological examinations.
Hematology, lymphocyte subsets, clinical chemistry, electrophoresis, and sta-
tistics. Hematology parameters were evaluated in EDTA-blood by routine pro-
cedures with a Contraves Autolyzer (AVL AG, Schaffhausen, Switzerland). Dif-
ferential counts were performed twice manually on 100 leukocytes (WBC).
Plasma protein and fibrinogen were determined by a refractometric method.
Feline CD41, CD81, and CD51 lymphocytes were determined in blood samples
by flow cytometry as described before (16). Briefly, whole blood samples were
defibrinated and indirectly stained with properly diluted culture supernatants
from hybridomas secreting monoclonal antibodies to feline CD4 or CD8 (1, 24).
Unconjugated primary antibodies were detected by fluorescein-conjugated
F(ab)2 goat anti-mouse immunoglobulin G (Milan Analytica AG, La Roche,
Switzerland). Stained blood samples were lysed with hypotonic formic acid, and
the labeled cells were analyzed in a Profile Analyzer (EPICS Division, Coulter
Immunology, Hialeah, Fla.). For dual color analysis, feline CD41, CD51, and
CD81 lymphocytes were stained with directly conjugated (fluorescein isothio-
cyanate or R-phycoerythrin) murine monoclonal antibodies (Southern Biotech-
nology Associates Inc., Birmingham, Ala.; 0.25 to 0.5 mg of immunoglobulin G
per 106 cells). The following biochemical parameters were assayed by automated
analysis (Cobas Mira; Hoffmann-La Roche AG, Basel, Switzerland) by standard
procedures recommended by the International Federation of Clinical Chemistry
as compiled by Tieze (65): bilirubin, glucose, urea, creatinin, protein, albumin,
cholesterol, triglyceride, alkaline phosphatase, aspartate aminotransferase
(AST), alanine aminotransferase, lipase, amylase, sodium, potassium, calcium,
and phosphorus. All samples from one collection date were analyzed within one
run. Serum protein electrophoresis was based on cellulose-acetate sheets
(Boskamp; Nanolab AG, Schlieren, Switzerland). Data obtained from the dif-
ferent groups were displayed or calculated by the box plot method (42). In all
figures displaying box plots, the box extends from the 25th percentile to the 75th
percentile, with a horizontal line at the median, and the whiskers extend down to
the smallest value and up to the largest value. Hematological and biochemical
parameters of the three FIV- and/or FeLV-positive groups and the negative
control group were analyzed for significant differences (P , 0.05) with the SAS
(Cary, N.C.) System for Windows 6.10 by the Kruskal-Wallis test (nonparametric
analysis of variance, SAS, proc npar1way wilcoxon). In addition, groups were
compared individually with the controls by the Wilcoxon rank sum test (SAS proc
npar1way wilcoxon).
RESULTS
Clinical outcome and survival. No severe clinical signs were
seen during the whole observation period in any of the surviv-
ing cats. Some animals showed mild stomatitis and gingivitis,
transient mild diarrhea, and loss of weight. All of the FIV-
positive cats survived; four of five cats viremic for FeLV had to
be euthanized for humane reasons (Fig. 1). One cat of group 3
had to be euthanized after only 2.5 years (Table 1). At nec-
ropsy, all of the four euthanized FeLV-positive cats showed
either lymphocytic or myeloid leukemia (Table 1). In summary,
1 of the 10 controls (group 1), four of the five persistently
FeLV-positive cats (group 3), and three of the five FIV-FeLV-
positive cats (group 4) had to be euthanized (Fig. 1). Necropsy
revealed lymphosarcomas in six of the eight cats (Table 1).
One cat showed signs of septicemia mediated by immune sup-
pression, and one cat suffered from myeloid leukemia.
Hematology.When the hematological parameters of groups
1 to 4 were analyzed by the Kruskal-Wallis test, only a few
significant differences were found. They were detected mainly
in the erythron: in erythrocyte (RBC) counts (P 5 0.0379), in
packed cell volume (PCV; P 5 0.0169), and in hemoglobin
(P 5 0.0466) at month 30, in mean corpuscular hemoglobin
concentration at month 19 (P 5 0.0058), in MCV (mean cor-
puscular volume) at month 64 (P 5 0.0214), and at different
time points in mean corpuscular hemoglobin (MCH; month
30, P 5 0.0109; month 43, P 5 0.0501; month 56, P 5 0.0499).
When the three positive groups, groups 2, 3, and 4, were
compared individually with group 1, FIV-positive cats had
lower PCVs (P5 0.0283), lower RBC counts (P5 0.0101), and
higher MCH values at month 30 (P5 0.0254) and higher mean
corpuscular hemoglobin concentration values at month 19
(P 5 0.0011) than the controls. Furthermore, FeLV-positive
cats twice had significantly higher MCH values (month 30, P5
0.0040; month 43, P 5 0.0365) (Fig. 2) than the controls, and
mean and median MCV scores of group 3 were constantly
higher compared with those of group 1 starting 30 months after
FIV infection (significantly higher at month 64; P 5 0.0160)
(Fig. 2).
FIG. 1. Survival of cats (percent) after FIV and/or FeLV infection and of controls.
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With the exception of FIV-FeLV-infected cats at month 19
(Fig. 3), no significant differences were found in total WBC
counts, although there were trends for lower WBC counts in
FIV-, FeLV-, and FIV-FeLV-positive cats at and after month
30 after FIV infection (Fig. 3). Furthermore, no significant
differences were found in the absolute differential counts.
Lymphocyte subsets. Relative and absolute CD41 counts
were determined at month 19 and in all samples collected
thereafter. They were significantly different between the four
groups at month 19 and after month 43 (P , 0.05). Compar-
ison of positive groups 2, 3, and 4 individually with the control
group 1 revealed lower relative CD41 counts in the FIV-
positive group 2 compared with that of group 1 at month 19
and at and after month 56 (P, 0.05) and lower absolute CD41
counts in group 2 starting 56 months after FIV infection (P ,
0.05) (Fig. 4). Surprisingly, the differences at month 43 were
due to lower relative (P 5 0.0338) and absolute CD41 counts
(P 5 0.0085) (Fig. 4) in the FeLV-positive group 3. The lowest
relative and absolute CD41 counts were found in group 4 (Fig.
4). No significant differences were found in CD81 counts.
CD41/CD81 ratios were significantly different between the
four groups of cats at and after month 43 (P , 0.05) due to
significant lower ratios in group 2 and group 4 (P , 0.05) (Fig.
5). The lowest ratios were seen in the FIV-FeLV-positive cats
of group 4 (Fig. 5). The decline of the ratio in group 2 was
predominantly caused by low CD41 lymphocyte counts. It was
paralleled by an increase of CD81 cells with low fluorescence
intensity described earlier (29). Sorted CD81 cells with low
fluorescence showed a blast-like morphology. Dual color anal-
ysis revealed that these cells were CD51. The lowest number of
CD41 cells (46 cells/ml) was measured at month 61 in FIV-
positive cat no. 261 (group 2), which was perfectly healthy at
that time.
Clinical chemistry and serum protein electrophoresis. Bio-
chemical parameters are to some degree influenced by feeding
and the time of blood collection. To minimize such factors, the
animals were always fasted for 16 h before blood sampling in
the early morning. As the cats became overweight, dry food
was restricted after month 30. However, cats of the four dif-
ferent groups always received the same amount and quality of
food. Significant differences in biochemical parameters be-
tween the FIV-positive cats and the FIV-negative controls are
summarized in Table 2. The major trends were the following:
glucose, phosphorus, protein, sodium, triglyceride, and urea
were higher and cholesterol was lower in group 2 than in the
controls. In the case of protein (Fig. 6), glucose (Fig. 7), and
urea, these trends appeared already between 9 and 19 months
after FIV infection. Based on electrophoresis of serum pro-
teins, absolute and relative gamma globulin fractions were
higher in group 2 (month 19 to 56; P , 0.05) (Fig. 6).
The FeLV-positive cats showed persistently higher AST and
urea levels (Table 3). In addition, urea was elevated in FIV-
FeLV-positive animals (significantly higher at month 19, P 5
0.0083; at month 30, P5 0.0319; and at month 43, P5 0.0446).
DISCUSSION
The aim of this study was to monitor experimental FIV-
and/or FeLV-infected cats over a period of many years under
well-controlled conditions to better characterize the asymp-
tomatic phases of the infections, obtain more insight into their
pathogenesis, and define easily measurable indicators for de-
velopment of disease. This latter aspect appears to be espe-
cially important in conjunction with the efficacy assessment of
FIV vaccines and antiretroviral drugs.
Clinical outcome and survival. The asymptomatic period of
FIV infection in the present study (group 2) without additional
cofactors was more than 6 years (Fig. 1), while under field
conditions, the asymptomatic phase was estimated to be short-
er (20, 36, 72). There are several facts that may explain this
apparently long asymptomatic period. (i) The cats in this study
were kept under optimal hygienic and ethological conditions.
We assume that this might be the most important reason for
the prolonged life expectancy compared with that in field cats.
(ii) The strain of FIV used, FIV Zurich 2, had been isolated
from a 7-year-old male cat suffering from emaciation and
therefore may be expected to induce disease. However, the
virus was kept in culture for several weeks prior to intraperi-
toneal inoculation into the cats of groups 2 and 4. The culti-
vation might have reduced the virulence of this strain. We
expect that some animals will show clinical signs of immuno-
deficiency shortly since CD41 counts in some of these cats
have dropped below 100 cells/ml.
In contrast to FIV, persistent FeLV infection had a much
more severe influence on the life expectancy of infected cats
although all cats were kept under the same conditions (Fig. 1).
TABLE 1. Euthanized cats: results of necropsy
Cat no.
Status of
blood test FIV
(mo)a
FeLV
(mo)b Results of necropsy
FIV FeLV
289 2 2 32 23 Generalized lymphosarcoma (tissue sections of the tumor were FeLV p27
positive by indirect immunoperoxidase assay)
286 1 1 34 24 Generalized necrotizing lymphadenitis; acute hepatitis with bacterial emboli
(septicemia?) and icterus; moderate membranoproliferative glomerulone-
phritis
268 1 1 34 24 Generalized necrotizing lymphadenitis and splenitis; hyperplasia of all lym-
phatic tissues
270 1 1 36 26 Generalized moderate lymphadenitis; hyperplasia of lymphatic tissues
264 2 1 40 31 Lymphosarcoma in gut wall, mesenteric lymph nodes, spleen, kidney, omen-
tum, and diaphragm
287 2 1 55 46 Lymphosarcoma in thymus, liver, several lymph nodes, and bone marrow;
hyperplasia of all lymphatic tissues
276 2 1 73 63 Myeloid leukemia; hyperplasia of lymphatic tissues
272 2 1 75 66 Lymphosarcoma in thymus, diaphragm, mesenteric lymph nodes, and kidney
aMonths after FIV infection took place in the experiment.
bMonths after FeLV infection took place in the experiment.
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Moreover, it comes as a surprise that four of four cats in this
group had neoplastic disease (Table 1). In the field, immuno-
deficiency and anemia are the predominant forms of chronic
FeLV infection. It may be speculated that because of the ideal
living conditions, our cats did not succumb to sequelae of
immunodeficiency and lived long enough for neoplasia to de-
velop (31 to 66 months of persistent FeLV viremia). In the
field, it was estimated that within 3.5 years of persistent FeLV
infection, 83% of infected cats would be dead (41).
Pedersen and coworkers (50) have shown that infection with
both FIV and FeLV leads to a more severe disease progression
than FIV infection alone. Our observation that by month 36,
three of five cats with FIV and FeLV infection (group 4) had
to be euthanized appeared to confirm this information (Table
1 and Fig. 1). However, in our study, the disease progression
was much less pronounced. This may be due to a lower viru-
lence of the FIV and FeLV strains we used. In addition, our
cats were first infected by FIV and then by FeLV, which differs
from the experimental design of Pedersen and coworkers.
However, it is unknown whether the order of infections is
important with respect to the outcome of the clinical course.
One cat (no. 289) is of special interest. This cat obviously
had recovered from FeLV infection—it remained FeLV p27
negative for the whole period. After it was euthanized because
of tumor development, the tumor was found to be histologi-
cally positive for FeLV p27 protein. We speculate that this
tumor development might be related to a systemic FeLV in-
fection which went unnoticed. This cat was assigned to the
FeLV-negative control group because it was consistently neg-
ative for p27 in serum, negative for virus isolation from the
serum and bone marrow cultures, developed high virus-neu-
tralizing antibodies, and therefore was considered immune to
FeLV infection.
Hematology. In earlier studies, FIV infection under field
conditions was associated with several hematological abnor-
malities such as leukopenia, lymphopenia, and neutropenia
(17, 62, 72). There are several possible explanations for the
absence of significant changes in WBC and differential blood
FIG. 2. Box plots of MCH (a) and MCV (b) in controls (n 5 10; shaded boxes) and FeLV-positive cats (n 5 5; no boxes shown because of small numbers). p, P ,
0.05 (Wilcoxon rank sum test).
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cell counts in the present study (Fig. 3). (i) For animal welfare
reasons, only a limited number of cats was used in the present
study. The chance to observe statistical differences was thus
reduced. (ii) The FIV Zurich 2 strain might be of lower viru-
lence than other field strains as mentioned above. (iii) The
results in the field studies were obtained from naturally in-
fected ill animals mostly at high risk for FIV infection (17, 62,
72). In the present study, the cats were from the same litters
and kept in identical rooms under identical conditions. There-
fore, many variables (other pathogens, age, sex, and surround-
ings), which may play an important role under field conditions,
were excluded. It might be speculated that FIV alone will
require a longer time to induce changes in WBC counts com-
pared with the field situation where FIV may act synergistically
with cofactors. The dramatic drop in WBC counts between
months 4 and 9 (Fig. 3) is due to the natural age-related
reduction of WBC counts (49).
Minor changes were found in the erythron. FIV-positive
animals showed slightly decreased PCV and RBC values 30
months after infection. This observation was accompanied by a
transient increase of MCH. During the early phase of this
experiment, blood was collected in weekly intervals. The de-
creased RBC count and PCV may reflect a somewhat lower
capability to regenerate the RBC in FIV-infected cats than in
noninfected animals. This, in turn, may be explained by de-
creases in the frequencies of marrow erythroid progenitors
previously reported in some FIV-positive cats (31, 58). FeLV
infection led to elevated values of MCH and MCV (Fig. 2), a
fact which has been described previously and which may be
FIG. 3. Box plots of total WBC counts in controls (n5 10; shaded boxes) and
FIV-positive cats (n 5 10; open boxes) (a), FeLV-positive cats (n 5 5; no boxes)
(b), and FIV-FeLV-positive cats (n 5 5; no boxes shown because of small
numbers) (c). p, P , 0.05 (Wilcoxon rank sum test).
FIG. 4. Box plots of absolute CD41 counts in controls (n 5 10; shaded
boxes) and FIV-positive cats (n 5 10; open boxes) (a), FeLV-positive cats (n 5
5; no boxes shown because of small numbers) (b), and FIV-FeLV-positive cats
(n 5 5; no boxes shown because of small numbers) (c). p, P , 0.05 (Wilcoxon
rank sum test).
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explained by the known interfering effect of FeLV on erythro-
cyte progenitor cells (47, 63).
Lymphocyte subsets. In FIV-positive cats, CD41/CD81 ra-
tios were lowered significantly mainly in long-term infection
(Fig. 5). The lowered CD41/CD81 ratio was predominantly
due to lowered CD41 counts (Fig. 4). Our finding that the
lowest ratio was seen in the FIV-FeLV-positive cats (Fig. 5) is
in agreement with other reports (50). In FeLV infection, im-
munosuppression may be explained by marked transient lym-
phopenia and neutropenia which take place during the primary
phase of the infection (49) and the immunosuppressive effect
of the protein p15E during chronic FeLV infection (25, 40,
67). In our study, we found that both CD41 (Fig. 4) and to a
lesser degree also CD81 lymphocytes were decreased in long-
term FeLV infection compared with that in noninfected con-
trols. Therefore, the CD41/CD81 ratio was not significantly
changed in these cats (Fig. 5). Similar observations were made
for short-term FeLV infection (53, 66). Based on our findings,
we postulate that in addition to the short-term depression of
lymphocyte counts and the malfunctioning of T lymphocytes
partly attributed to p15E (25, 40), a decrease of mainly CD41
lymphocytes is an important factor in long-term FeLV-induced
immunosuppression.
Clinical chemistry. The most consistent changes in biochem-
ical parameters in FIV-infected cats were increased glucose
and protein values and decreased cholesterol levels already
early in infection and increased triglyceride values later in FIV
infection (Table 2). Elevated concentrations of glucose (Fig. 7)
may reflect changes in the energy metabolism of FIV-infected
cats. Whether elevated glucose levels in our FIV-infected cats
may reflect a hypermetabolic state (11, 70) associated with
subclinical hypercortisolemia as is commonly found in human
immunodeficiency virus (HIV)-infected humans (11) remains
to be elucidated. Stress as a cause of hyperglycemia can be
ruled out since our cats were highly accustomed to the care-
takers and veterinarians and were slightly sedated for the
blood collection. In addition, living conditions and blood col-
lection procedures were identical for all cats.
The elevated concentrations of serum protein in FIV-in-
fected cats (Table 2 and Fig. 6) could readily be explained by
the increased gamma globulin levels found in these animals
FIG. 5. Box plots of CD41/CD81 ratio in controls (n 5 10; shaded boxes)
and FIV-positive cats (n 5 10, open boxes) (a), FeLV-positive cats (n 5 5; no
boxes shown because of small numbers) (b), and FIV-FeLV-positive cats (n 5 5;
no boxes shown because of small numbers) (c). p, P , 0.05 (Wilcoxon rank sum
test).
TABLE 2. Differences in biochemical parameters in
FIV-positive cats versus controls
Parameter Moa
Valueb in:
PcControls FIV posi-tive cats
5% 50% 95% 5% 50% 95%
Cholesterol (mmol/liter) 56 7.7 9.4 12.7 4.7 8.1 9.3 0.0453
Glucose (mmol/liter) 9 3.2 3.7 4.5 3.5 4.4 4.9 0.0535
19 4.0 4.3 4.7 4.2 4.7 5.3 0.0439
43 4.8 5.1 5.4 4.7 5.8 8.5 0.0403
56 4.8 5.3 5.6 5.3 6.3 7.2 0.0052
64 4.3 4.7 5.0 4.4 5.2 5.9 0.0594
75 4.6 4.8 5.0 4.6 5.1 5.3 0.0234
Lipase (U/liter) 9 7.5 11 26.7 16 24 32.2 0.0369
Phosphorus (mmol/liter) 43 1.1 1.2 1.4 1.2 1.4 1.5 0.0171
56 1.3 1.4 1.6 1.5 1.6 1.9 0.0017
64 1.1 1.3 1.4 1.2 1.3 1.6 0.0838
Protein (g/liter) 19 62 68 76 69 73 79 0.0376
43 62 64 69 64 66 70 0.0722
56 66 69 73 70 72 80 0.0262
73 62 66 70 66 68 75 0.0482
79 63 65 69 66 69 73 0.0215
Sodium (mmol/liter) 43 161 162 165 162 165 168 0.0204
56 156 156 158 157 160 163 0.0046
75 150 156 157 155 157 159 0.0636
Triglyceride (mmol/liter) 56 0.4 0.4 0.7 0.4 0.5 1.6 0.0361
73 0.2 0.4 0.5 0.4 0.6 0.9 0.0102
Urea (mmol/liter) 19 7.7 9.2 10.7 8.8 10.4 13.0 0.0256
30 8.3 9.0 10.7 9.0 10.2 11.7 0.0410
aMonths after FIV infection took place in the experiment.
b Values are given for 5% quantile, median, and 95% quantile.
c By Wilcoxon rank sum test.
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(Fig. 6). Hypergammaglobulinemia is associated with FIV in-
fection (58, 62, 64), may reflect a polyclonal activation of the
humoral immune response (1, 28), and is also a consistent
finding in HIV-infected humans (3, 26, 30, 56). It is interesting
to note that the statistically significant differences in the
gamma globulins disappeared after month 56 (Fig. 6). This was
due to an increased variance of the gamma globulin fraction in
the FIV-positive cats and may reflect the beginning of a de-
creased B-cell activation and, with it, an additional step to-
wards immune suppression in some of the FIV-positive cats.
The observation that cholesterol levels were decreased and
triglyceride values were increased in FIV-positive cats is in
striking agreement with the situation in HIV infection (13, 43,
60). Alterations in lipid metabolism are known to occur during
a variety of infections (2, 4, 27, 55) and may reflect the stage
and severity of disease (5). In HIV-infected humans, lipid
metabolism is known to be disturbed already in the asymptom-
atic phase (15). Cytokines such as tumor necrosis factor alpha,
interleukin-1, and interferons are discussed as mediators of
these metabolic alterations (12, 13). Alpha interferon levels
are correlated with triglyceride levels, prolonged triglyceride
clearance time (13), and increased de novo hepatic lipogenesis
(15). The cytokine profile of our cats remains to be investi-
gated. Regardless of the cause, these alterations are of partic-
ular interest in the context of the immune status of the infected
individuals since they may influence cellular functions, for ex-
ample, through changes in lipid membrane composition: the
function of both the humoral and cellular immune systems may
be impaired by these changes (9, 43, 60). Changes in serum
lipid levels may therefore further contribute to the pathogen-
esis of AIDS in humans and the AIDS-like disease in FIV-
infected cats.
FIG. 6. Box plots of serum protein levels (a) and absolute gamma globulins (b) in controls (n 5 10; shaded boxes) and FIV-positive cats (n 5 10; open boxes). p,
P , 0.05 (Wilcoxon rank sum test).
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In addition, analysis of biochemical parameters revealed sys-
tematically higher urea levels in the FIV-positive (Table 2), the
FeLV-positive (Table 3), and FIV-FeLV-positive cats com-
pared with that in controls. Furthermore, phosphorus was sig-
nificantly increased in FIV-positive cats after the feed change
towards more canned food. There are several physiological
factors which can influence the blood phosphorus values such
as phosphorus intake or age of the animal or hemolysis of the
sample. Since blood samples were always taken with utmost
care, thereby minimizing hemolysis, and centrifugation and
collection of sera were accomplished at the same time for all
samples, elevated phosphorus values in FIV-positive animals
may not be attributed to handling errors. Furthermore, age-
dependent differences in phosphorus levels can be ruled out in
this study because the animals of the four groups were age
matched and, also, an influence of the food can be excluded as
mentioned above. Elevated urea and phosphorus levels in FIV-
positive cats may therefore be associated with a mild kidney
dysfunction accompanied by a decreased glomerular filtration
rate. A closer look at creatinine values of FIV-infected cats
also revealed slightly higher mean creatinine levels in FIV-
positive cats beginning 43 months after FIV infection (data not
shown). These subclinical changes in kidney function may, with
prolonged duration of FIV infection, also reflect pathologic
alterations in the kidney. In naturally FIV-infected cats, kidney
abnormalities such as mesangial widening and segmental dif-
fuse glomerulosclerosis or glomerulonephritis were reported
(51, 54). Immune complexes deposited in the glomerula of
FIV-infected cats may contribute to a decreased glomerular
filtration rate (52). Moreover, elevated urea levels in FeLV-
positive and FIV-FeLV-positive animals may be explained by a
mild kidney dysfunction since FeLV infection is known to lead
to glomerulonephritis (7, 21) partly due to deposition of cir-
culating immune complexes (8, 61).
Sodium values were elevated in FIV-infected cats at some
time points of the observation period (Table 2). No explana-
tion can be given for this observation, since sodium intake
levels were similar for all four groups, water was available ad
libitum, room temperature was constant, and no dehydration
was found upon clinical examination. A slight elevation of
lipase levels was found in FIV-positive cats compared with that
in controls beginning already 9 months after infection (Table
2). Pancreatitis was observed in some HIV-infected patients
(44) but was at least partly attributed to infections with other
pathogens such as cytomegalovirus or secondary effects of an-
tiretroviral treatment (44, 71). Markedly elevated lipase values
are associated with pancreatitis in the cat as well. Since pan-
creatitis is not known to occur in FIV infection and we did not
have any clinical or laboratory evidence of pancreatitis, the
slightly increased values of lipase found in the FIV-positive
cats may be indicative of beginning kidney dysfunction and
therefore may be in agreement with the findings described
above.
In FeLV-infected animals, elevated AST levels were ob-
served (Table 3). This phenomenon may be explained by mi-
crohemolytic processes not detected by the naked eye possibly
caused by adsorption of FeLV to the surface of erythrocytes
(45).
It is interesting to note that although the differences in
biochemical parameters between FIV-positive and -negative
cats were significant, most of the values still lay within the
reference ranges evaluated for field cats in our laboratory.
These differences were detected by comparing the parameters
under study with those of a control population strictly matched
for age and living conditions. This underlines the importance
of appropriate control populations.
FIG. 7. Box plots of glucose values in controls (n 5 10; shaded boxes) and FIV-positive cats (n 5 10; open boxes). p, P , 0.05 (Wilcoxon rank sum test).
TABLE 3. Differences in biochemical parameters in
FeLV-positive cats versus controls
Parameter Moa
Valueb in:
PcControls FeLV-positive cats
5% 50% 95% 5% 50% 95%
AST (U/liter) 30 15.5 19.5 23.7 21.6 25.0 50.2 0.0165
43 16.2 21.0 26.4 21.6 28.0 39.5 0.0524
56 18.0 20.0 24.6 23.0 23.0 41.9 0.0926
73 16.8 20.0 23.6 36.1 36.5 37.0 0.0432
Urea (mmol/liter) 19 7.7 9.2 10.7 11.3 11.6 12.2 0.0048
73 10.2 11.9 14.6 15.3 16.8 18.3 0.0451
aMonths after FIV infection took place in the experiment.
b Values are given for 5% quantile, median, and 95% quantile.
c By Wilcoxon rank sum test.
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In conclusion, the important parameters of disease progres-
sion were glucose, protein, gamma globulins, urea, cholesterol,
and CD41 counts in FIV infection and MCV, MCH, urea,
AST, and CD41 counts in FeLV infection. Monitoring of these
parameters may prove useful for the evaluation of candidate
FIV vaccines and antiretroviral drugs in cats. The many par-
allels between laboratory parameters in FIV and HIV infection
further support the importance of FIV as a model for HIV (6,
10, 22).
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